Search





Search





Markets
/
Stocks
/
abbv
/

AbbVie Inc

ABBV

Add to Watchlist

256.910USD

+3.610+1.43%

Close 07-23 16:00（ET）Quotes delayed by 15 min

453.89BMarket Cap

126.46P/E TTM

AbbVie Inc

256.910

+3.610+1.43%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+1.43%

5 Days

+0.99%

1 Month

+9.44%

6 Months

+17.17%

Year to Date

+12.44%

1 Year

+34.83%

Key Figures

255.610Open

258.380High

4.62MVolume

126.46P/E TTM

15.67P/E Dynamic

6.740Dividend TTM

0.26%Turnover Ratio

253.300Prev. Close

253.100Low

610.75MTurnover

107.10P/E Static

-68.19P/B

2.62%Div Yield TTM

2.67%ROA

244.81052wk High

0.84Volume Ratio

4.24BNet Profit

1.77BShares

2.0316EPS TTM

0.31Beta

15221.82%ROE

181.73052wk Low

2.08%Amplitude

71.88%Gross Margin

453.89BMarket Cap

5.32Reward/Risk

1.47%Risk Rate

TradingKey Stock Score of AbbVie Inc

Currency: USD Updated: 2026-07-23

Key Insights

AbbVie Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 265.35.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AbbVie Inc's Score

Industry at a Glance

Industry Ranking

20 / 155

Overall Ranking

55 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

48°C



Very Low

Very High

Positive+

AbbVie Inc Highlights

StrengthsRisks

AbbVie Inc. is an American pharmaceutical firm based in North Chicago, Illinois. Its prominent products include Humira, which is approved for treating autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis, and is administered through injection; Skyrizi, an interleukin-23 inhibitor also aimed at treating autoimmune disorders; Rinvoq, utilized for arthritis management; and Botox. Other significant offerings comprise Imbruvica for cancer treatment, Vraylar for schizophrenia and bipolar disorder, Venclexta for leukemia and lymphoma, and Mavyret for Hepatitis C treatment. The company is also dedicated to advancing therapies for additional conditions such as cancer, neurologic diseases, eye care, and cystic fibrosis.

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 263.76%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 263.76%.

Overvalued

The company’s latest PE is 126.46, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.36B shares, increasing 1.92% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 14.48M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.39.

Analyst Rating

Based on 33 analysts

Buy

Current Rating

265.349

Target Price

+3.61%

Upside Space

AbbVie Inc News

What Are Good Stocks to Invest in Right Now?

TradingKey - Investors like to think that timing the bottom of the stock market is extremely difficult. An expert may get it wrong – as evidenced by many recent mistakes made by professional investors.

TradingKeyWed, Feb 4

Earnings Forecast

Analyst Rating

Based on 33 analysts

Buy

Current Rating

265.349

Target Price

+3.61%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

AbbVie Inc

ABBV

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Pfizer Inc

PFE

Merck & Co Inc

MRK

...

Indicators

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-1.243

Neutral

RSI(14)

64.064

Neutral

STOCH(KDJ)(9,3,3)

68.882

Buy

ATR(14)

5.947

Low Volatility

CCI(14)

73.531

Neutral

Williams %R

22.582

Buy

TRIX(12,20)

0.395

Sell

StochRSI(14)

76.961

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

254.838

Buy

MA10

251.355

Buy

MA20

252.009

Buy

MA50

232.265

Buy

MA100

222.000

Buy

MA200

223.862

Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

AbbVie Inc Info

AbbVie is ranked sixth among the largest biomedical companies by revenue and holds the 108th position on the Forbes Global 2000 list.

The name "AbbVie" originates from a combination of "Abbott," the name of its former parent company, and "vie," which refers to a Latin root meaning 'life.'

Ticker SymbolABBV

CompanyAbbVie Inc

CEOMichael (Robert A)

Websitehttps://www.abbvie.com/